Dataset changelog
This page records dated changes to the dataset and the news that moved prices. Corrections of our own errors are logged separately at /corrections/.
Released · Last reviewed · how we verify
November 20 re-read
Every program re-read on its own page (2026-11-21 00:33–00:57 UTC; NexLife’s plan pages checked again later the same day). Changed: Yucca Health tirzepatide $139 a month month to month, $119 on 12 months (August: $258 on a 6-month new-patient plan); Found $339 per 28-day cycle month to month, $199 on a 12-month term (was $359 and $239); Fifty 410 a $199 four-week or $299 eight-week tirzepatide program (was a $399 three-month starter); Mochi Health prints $90 tirzepatide and $60 semaglutide at the starting dose plus a $79 monthly membership; Noom Med prints $299 tirzepatide and $249 semaglutide per four weeks after the first four weeks, billed every 12 weeks; Lavender Sky Health’s lowest semaglutide starter is $135; Oak Longevity “from $109”; Henry Meds prints no injectable tirzepatide price; SkinnyRx showed only a $99 first month; Amble shows only “plans starting at $99”. Unchanged: NexLife, Eden, IVIM Health, Remedy Meds, OrderlyMeds, ShedRx, Enhance.MD. Not readable: TrimRx, MEDVi, bmiMD, Embody, Ro, Hims & Hers.
Added: Mondae ($126 tirzepatide, $87 semaglutide) and Collective ($69 and $59 plus a $199 yearly membership). Site: computed ranking published; 94/100 claim withdrawn (COR-006); provider, head-to-head, alternatives, state and cost pages rebuilt from the re-read (COR-007); 255 three-program comparisons merged into their closest pair and 84 duplicate question and cost pages merged, all with 301 redirects; two new articles.
News that matters to cash-pay buyers
- November 20, 2026: Every program re-read. Yucca Health now prints $139 a month for tirzepatide (was $258 in August); Found $339 per 28-day cycle (was $359); Fifty 410 a $199 four-week program; Noom Med and Mochi Health print compounded prices; Mondae and Collective added to the dataset; NexLife and Eden unchanged.
- November 20, 2026: Computed ranking published. Every compounded program scored on pricing transparency and annual cost: Mondae 35.5 of 40, Yucca Health 34.6, Eden 34.3, NexLife 33.6. NexLife stays the featured pick as a labelled editorial selection; the earlier 94/100 claim was withdrawn.
- November 9, 2026: FDA requires an eye-risk warning on GLP-1 labels. FDA’s Drug Safety Communication adds NAION, a rare optic-nerve condition, to the labels of approved GLP-1 receptor agonists; FDA does not address compounded products.
- November 6, 2026: Lilly and Hims & Hers. Hims patients can buy Zepbound (from $299) and Foundayo (from $149) at Lilly’s self-pay prices; Hims says it will not offer compounded copies of Lilly’s drugs. No Hims fee was stated.
- November 5, 2026: LifeMD ships Lilly brand drugs (reported). LifeMD says its affiliated pharmacy will dispense Zepbound and Foundayo at Lilly’s self-pay prices; its $149 monthly program fee is extra.
- November 2, 2026: Medicare’s negotiated semaglutide price. CMS: Ozempic, Rybelsus and Wegovy at $274 for a 30-day supply in Medicare from January 1, 2027. Cash prices are not affected.
- October 30, 2026: FDA warning letter to RonanRx. Letter 737905 cites “FDA-approved compounded medications” and “American made” claims by a telehealth seller.
November update
NexLife prices (read November 6 and 8, 2026). Compounded tirzepatide $129 a month month to month and $125/$119/$115 on 3/6/12-month plans (October 15, 2026 read: $169/$159/$149/$139; August capture: $215/$195/$190/$186); compounded semaglutide $109 and $105/$99/$95 (October 15: $139/$132/$125/$119; August: $165/$149/$147/$145). Microdose plans now cost the same as the standard plans (tirzepatide was $189, semaglutide $129). Sublingual tablet prices unchanged.
October 15, 2026 re-reads. Eden: tirzepatide $129 and semaglutide $99 a month, no membership (was $408 and $198 all-in with a $99 membership). Found: $359 per 28-day cycle month to month, $239 on a 12-month term (was a $289 third-party figure). IVIM Health: tirzepatide “starting at $117/mo + $75/mo Program Fee”; semaglutide “starting at $65/mo”. ShedRx: tirzepatide “starting as low as $239/mo”. Henry Meds: GLP-1 “starts at $179/month”, no molecule price; Mochi Health and LifeMD: no compounded price printed. Remedy Meds, SkinnyRx and Yucca Health: not readable; August figures kept.
Site. 90 three-program comparisons that included NexLife now redirect to the matching NexLife pair page; one provider record removed; two new articles; dated update notices on pages that still show August figures.
Developments that matter to cash-pay buyers
- : NexLife lowers its standard prices (above).
- : Medicare open enrollment opens (through December 7); Lilly scheduled its third-quarter results for October 29.
- : CNBC reports Walmart will cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027, still not for weight loss.
- : Ozari Health announces two plans in a paid press release (compounded tirzepatide from $125 a month); not in our dataset.
- : FDA updates its page on unapproved GLP-1s (retatrutide and cagrilintide cannot be used in compounding; 28-day discard rule for compounded multi-dose vials). Rhode Island Medicaid ends coverage of GLP-1s prescribed solely for weight loss.
- : CMS’s BALANCE page answers “the BALANCE Model not launching in Medicare in 2027”; the Medicare GLP-1 Bridge runs through December 31, 2027 ($50 copay; Foundayo, Wegovy and the Zepbound KwikPen only).
- : FDA warning letter 738238 to Empower Pharmacy over compounded tirzepatide and semaglutide products it says “appear to be essentially copies” of approved drugs.
- : FDA proposes not to place semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431); no final decision found as of October 15, 2026.
Launch
Initial public dataset of 41 programs from captures dated August 5 to 9, 2026; brand figures read August 9, 2026.